KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Current Taxes (2016 - 2020)

Historic Current Taxes for Supernus Pharmaceuticals (SUPN) over the last 5 years, with Q2 2020 value amounting to $25.1 million.

  • Supernus Pharmaceuticals' Current Taxes rose 83687.36% to $25.1 million in Q2 2020 from the same period last year, while for Jun 2020 it was $25.1 million, marking a year-over-year increase of 83687.36%. This contributed to the annual value of $2.4 million for FY2019, which is 8026.18% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Current Taxes of $25.1 million as of Q2 2020, which was up 83687.36% from $9.1 million recorded in Q1 2020.
  • Supernus Pharmaceuticals' 5-year Current Taxes high stood at $25.1 million for Q2 2020, and its period low was $7000.0 during Q4 2016.
  • Moreover, its 5-year median value for Current Taxes was $7.5 million (2017), whereas its average is $8.9 million.
  • Its Current Taxes has fluctuated over the past 5 years, first surged by 22758571.43% in 2017, then plummeted by 8026.18% in 2019.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Current Taxes stood at $7000.0 in 2016, then soared by 227585.71% to $15.9 million in 2017, then dropped by 22.34% to $12.4 million in 2018, then tumbled by 80.26% to $2.4 million in 2019, then skyrocketed by 925.46% to $25.1 million in 2020.
  • Its last three reported values are $25.1 million in Q2 2020, $9.1 million for Q1 2020, and $2.4 million during Q4 2019.